Merck stock falls 1.60% and underperforms rivals

6 articles · Updated · MarketWatch · Apr 30

Shares closed at $109.18 on Thursday as the S&P 500 rose 1.02% and the Dow gained 1.62%.
Merck finished 12.75% below its 52-week high of $125.14 reached on 25 February.
It lagged Johnson & Johnson, Pfizer and Eli Lilly, while trading volume of 16.6 million topped its 50-day average of 9.8 million.

Merck’s stock plunged despite beating revenue forecasts. Is its costly acquisition strategy brilliant or just reckless?

As its cancer drugs boom, why is Merck’s blockbuster Gardasil vaccine suddenly collapsing in key global markets?